Free Newsletter
SPOTLIGHT: Avandia cleared FDA by one vote
Free newsletter via e-mail
Tools
SPOTLIGHT ... Avandia cleared FDA by one vote
Behind closed doors, the FDA's safety board barely backed GlaxoSmithKline's Avandia last month, voting 8-to-7 to keep the drug on the market with tougher warnings of heart risks rather than pull it completely. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: